Mumbai: Japan-headquartered Takeda Pharmaceutical and Advinus Therapeutics, privately held drug major promoted by the Tata Group, have entered into an agreement to initiate a three-year discovery collaboration. The alliance will focus on novel targets for therapeutic areas including inflammation, central nervous system and metabolic diseases.
Advinus will be responsible for leading the programmes to create optimal investigational new drug (IND) ready compounds for pre-defined targets.
It Advinus will receive research funding of $36 million, $9 million in milestones leading to candidate selection, and is eligible to receive future clinical and regulatory milestone payments of up to $45 million per product, plus royalties on product sales worldwide. Under the terms of the agreement, Takeda is to receive worldwide commercial rights to drug candidates emerging from this alliance.
No comments:
Post a Comment